Literature DB >> 9465546

Estimation of the future numbers of patients with mental disorders in Japan based on the results of National Patient Surveys.

Y Nakamura1, T Ojima, I Oki, S Tanihara, H Yanagawa.   

Abstract

To estimate the future numbers of patients with mental disorders, schizophrenic disorders, and neurotic disorders, prevalence obtained from the National Patient Surveys conducted by the Ministry of Health and Welfare of the Japanese government was projected by using linear models by age and sex. The prevalence of whole mental disorders and neurotic disorders will increase, while that of schizophrenic disorders will not do so much. The numbers of patients with mental disorders were estimated to be 973 thousand for males and 1,359 thousands for females in the year of 2008, which were 622 thousand and 733 thousand in 1993, respectively. The disease-specific numbers in 2008 were 562 thousand for schizophrenic disorders and 867 thousand for neurotic disorders, both were 451 and 437 thousand in 1993, respectively. Because of the increase of old age population, the number of old patients with each disorder will also become large.

Entities:  

Mesh:

Year:  1997        PMID: 9465546     DOI: 10.2188/jea.7.214

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


  3 in total

Review 1.  A systematic review of the prevalence of schizophrenia.

Authors:  Sukanta Saha; David Chant; Joy Welham; John McGrath
Journal:  PLoS Med       Date:  2005-05-31       Impact factor: 11.069

2.  The cost of schizophrenia in Japan.

Authors:  Mitsuhiro Sado; Ataru Inagaki; Akihiro Koreki; Martin Knapp; Lee Andrew Kissane; Masaru Mimura; Kimio Yoshimura
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-30       Impact factor: 2.570

Review 3.  An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review.

Authors:  Jason C Simeone; Alexandra J Ward; Philip Rotella; Jenna Collins; Ricarda Windisch
Journal:  BMC Psychiatry       Date:  2015-08-12       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.